Jurisdictional Statutory Assessment
Statutory shield law guarantees patient and provider autonomy over embryo creation, cryopreservation, testing, and chosen disposition.
Statutory shield law guarantees patient and provider autonomy over embryo creation, cryopreservation, testing, and chosen disposition.
Why this tool matters: The rapid convergence of Assisted Reproductive Technology (ART)—including In Vitro Fertilization (IVF), Preimplantation Genetic Testing (PGT-A, PGT-M, and novel PGT-P polygenic risk scores), and gestational surrogacy—has met a deeply fractured legal environment following the U.S. Supreme Court's Dobbs decision and subsequent state rulings such as the Alabama Supreme Court's LePage v. Mobile Infirmary (2024), which classified cryopreserved extrauterine blastocysts as legal persons under the state's Wrongful Death of a Minor Act.
Three Core Statutory Tiers:
1. Safe Harbor / Shield Jurisdictions (e.g., California AB 2099, New York, Massachusetts, Illinois): Explicitly protect IVF providers, patients, and cryogenic storage facilities against out-of-state subpoenas and civil/criminal liability for embryo creation, testing, and elective disposition.
2. Neutral / Ambiguous Jurisdictions: Recognize embryos as an intermediate category of "special respect" (neither pure persons nor mere chattel property), leaving clinics reliant on mutual contract law for cryo-disposition.
3. Strict Personhood / High-Risk Jurisdictions: Define embryonic human life beginning at fertilization. Any accidental freeze-thaw failure or deliberate discard of an aneuploid or un-implanted blastocyst carries potential civil wrongful death litigation, prompting clinic pauses and interstate transport demands.
Polygenic Testing (PGT-P) Controversies: While PGT-M targets high-penetrance single-gene mutations (e.g., Huntington's, BRCA1/2, Cystic Fibrosis) with broad ethical consensus, PGT-P ranks embryos by polygenic risk scores for complex multifactorial traits and chronic diseases (e.g., diabetes, coronary artery disease, cognitive traits). Critics such as bioethics advocates and conservative policy institutes argue PGT-P crosses into eugenic selection, prompting legislative proposals for federal or state bans on embryo grading beyond monogenic disease prevention.